Journal of Molecular Medicine

, Volume 83, Issue 12, pp 976–983 | Cite as

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

  • Harri Sihto
  • Marjut Puputti
  • Laura Pulli
  • Olli Tynninen
  • Walter Koskinen
  • Leena-Maija Aaltonen
  • Minna Tanner
  • Tom Böhling
  • Tapio Visakorpi
  • Ralf Bützow
  • Aija Knuuttila
  • Nina N. Nupponen
  • Heikki Joensuu
Original Article

Abstract

Mutations that may predict response to adenosine 5′-triphosphate (ATP)-mimetic epidermal growth factor receptor (EGFR) inhibitors occur in the EGFR kinase domain in lung adenocarcinomas and bronchioloalveolar carcinomas (BACs). Data on the frequency of EGFR mutations are sparse in other human tumors. Apart from the deletion mutant EGFRvIII, little is known about the frequency of mutations that encode for the EGFR extracellular domains II and IV that participate in receptor dimerization and formation of the tethered (autoinhibited) receptor conformation. We investigated 566 human neoplasms consisting of various histological types for mutations in exons 6, 7 (encode domain II), 14, 15 (domain IV), 18, 19, and 21 (the kinase domain) using denaturing high-performance liquid chromatography (DHPLC). Approximately 4,500 EGFR exons were screened for the presence of a mutation, and samples with an abnormal finding in DHPLC were sequenced. Only one mutation was found in the extracellular domain IV (glioblastoma), and none in domain II. Eight (11%) out of the 40 lung adenocarcinomas, or 33 BACs, investigated had exon 19 or 21 mutation in the kinase domain, but no mutations were found in other tumor types. Most of the lung cancers with mutated EGFR had three to six copies of the mutated gene in fluorescence in situ hybridization. We conclude that mutations of the EGFR kinase domain and the cysteine-rich extracellular domains are infrequent in most types of human cancer apart from lung adenocarcinoma. Mutated EGFR is usually not amplified in lung cancer.

Keywords

Epidermal growth factor receptor Tyrosine kinase receptors Lung neoplasms Glioblastoma Mutation 

Abbreviations

EGFR

Epidermal growth factor receptor

BAC

Bronchoalveolar carcinoma

DHPLC

Denaturing high-performance liquid chromatography

FISH

Fluorescence in situ hybridization

NSCLC

Non-small cell lung cancer

PCR

Polymerase chain reaction

Notes

Acknowledgements

Supported by grants from the Cancer Society of Finland, Foundation for the Finnish Cancer Institute, the Sigrid Juselius Foundation, and the Research Funds of Helsinki University Central Hospital.

References

  1. 1.
    Yarden Y, Sliwkowski M (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMedGoogle Scholar
  2. 2.
    Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(Suppl 2):21–26CrossRefGoogle Scholar
  3. 3.
    Herbst R, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 94:1593–1611CrossRefPubMedGoogle Scholar
  4. 4.
    Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B (1987) Increased expression of epidermal growth factor receptor gene in malignant gliomas is variably associated with gene amplification. Proc Natl Acad Sci U S A 84:6899–6903PubMedGoogle Scholar
  5. 5.
    Scagliotti GV, Selvaggi G, Novello S, Hirsch FR (2004) The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10:4227s–4232sPubMedGoogle Scholar
  6. 6.
    Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965–2969PubMedGoogle Scholar
  7. 7.
    Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMedGoogle Scholar
  8. 8.
    Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ (2003) Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94:50–56PubMedGoogle Scholar
  9. 9.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  10. 10.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  11. 11.
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311CrossRefPubMedGoogle Scholar
  12. 12.
    Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195–8203PubMedGoogle Scholar
  13. 13.
    Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167–1173PubMedGoogle Scholar
  14. 14.
    Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346PubMedGoogle Scholar
  15. 15.
    Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that inhibit ectodomain dimerization. Mol Cell 11:507–517CrossRefPubMedGoogle Scholar
  16. 16.
    Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J (2004) The tethered configuration of the EGF receptor extracellular domain exerts only limited control of receptor function. Proc Natl Acad Sci U S A 101:923–928PubMedGoogle Scholar
  17. 17.
    O’Donovan MC, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C, Speight G, Upadhyaya M, Sommer SS, McGuffin P (1998) Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics 52:44–49PubMedGoogle Scholar
  18. 18.
    Han S, Cooper DN, Upadhyaya M (2001) Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 109:487–497PubMedGoogle Scholar
  19. 19.
    Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H (2005) KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23:49–57PubMedGoogle Scholar
  20. 20.
    Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi OP, Isola JJ (1994) Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry 16:93–99PubMedGoogle Scholar
  21. 21.
    Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F (2005) EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865PubMedGoogle Scholar
  22. 22.
    Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493–2501PubMedGoogle Scholar
  23. 23.
    Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22:1103–1109PubMedGoogle Scholar
  24. 24.
    Barber TD, Vogelstein B, Kinzler KW, Velculescu VE (2005) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883PubMedGoogle Scholar
  25. 25.
    Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH (2005) Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 113:510–511PubMedGoogle Scholar
  26. 26.
    Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879–2882PubMedGoogle Scholar
  27. 27.
    Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825PubMedGoogle Scholar
  28. 28.
    Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Harri Sihto
    • 1
  • Marjut Puputti
    • 1
  • Laura Pulli
    • 1
  • Olli Tynninen
    • 2
  • Walter Koskinen
    • 3
  • Leena-Maija Aaltonen
    • 3
  • Minna Tanner
    • 5
  • Tom Böhling
    • 2
  • Tapio Visakorpi
    • 6
  • Ralf Bützow
    • 2
  • Aija Knuuttila
    • 4
  • Nina N. Nupponen
    • 1
  • Heikki Joensuu
    • 7
  1. 1.Laboratory of Molecular OncologyHelsinkiFinland
  2. 2.Department of PathologyHelsinki University Central Hospital (HUSLAB) and University of HelsinkiHelsinkiFinland
  3. 3.Otorhinolaryngology-Head and Neck SurgeryHelsinki University Central HospitalHUSFinland
  4. 4.Department of Pulmonary MedicineHelsinki University Central HospitalHUSFinland
  5. 5.Department of OncologyTampere University Central HospitalTampereFinland
  6. 6.Institute of Medical TechnologyUniversity of Tampere and Tampere University HospitalTampereFinland
  7. 7.Department of OncologyHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations